TY - JOUR T1 - Treatment of early undiagnosed airflow obstruction in patients of OSA on CPAP improves sleep quality and symptoms JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3580 VL - 58 IS - suppl 65 SP - PA3580 AU - Tarang Kulkarni AU - Sovan Kanti Chakraborty AU - Raja Dhar AU - Milind Sovani Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3580.abstract N2 - Introduction: In cases of controlled Obstructive sleep apnea, co-existent untreated airflow obstruction could lead to further impairment in sleep quality.Aim: To assess whether treatment of undiagnosed underlying airflow obstruction in patients with OSA on CPAP therapy will lead to improved sleep quality.Methods: Patients with OSA and established on CPAP therapy for 3 months were included and subjected to spirometry. COPD assessment test(CAT) score, Pittsburg Sleep Quality Index(PSQI), Functional Outcome of Sleep Questionnaire 10(FOSQ-10), and Epworth Sleepiness(ESS) score were recorded at baseline for all and after 6 weeks of treatment in those with airflow obstruction. This was defined as FEV1/VC<70% or FEV1/VC<70-75% with CAT score>10. Patients with COPD (smoking history>20 pack-years) underwent therapy with Indacaterol/Glycopyrronium inhaler for six weeks. Patients with asthma were treated with formoterol/budesonide.Results: Of 104 patients (mean age 57.1years), 37 (35.6%) patients (23 men) had an overlap of OSA and airflow obstruction. Out of these 37 patients, 22 were diagnosed with asthma, 15 with COPD. 13 (12.5%) patients from the overlap group had FEV1/VC<70% on spirometry, 24 patients(23.0%) had a FEV1/VC 70-75% with CAT score>10. Significant improvement (p<0.001) was observed in PSQI(-1.14), ESS(-1.6), and CAT(-2.8) after 6 weeks of treatment of underlying airways disease.Conclusion: Sleep quality and symptoms can be improved with the treatment of underlying early airflow obstruction. We would recommend that in patients with OSA, smoking/exposure history and CAT score should be considered and those at risk should be subjected to spirometry to assess need for treatment.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3580.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -